TYRA
HealthcareTyra Biosciences, Inc. · Biotechnology · $2B
What is Tyra Biosciences, Inc.?
Tyra Biosciences is a preclinical-stage biopharmaceutical company focused on developing targeted therapies designed to overcome tumor resistance in cancer patients. Headquartered in Carlsbad, California, the company is building a pipeline around fibroblast growth factor receptor inhibition.
Tyra Biosciences generates no commercial revenue at this stage — instead, it invests in research and development to advance drug candidates through clinical trials. The company's lead program targets FGFR3 in muscle invasive bladder cancer. Additional programs address FGFR2-driven intrahepatic cholangiocarcinoma, FGFR3-related achondroplasia, RET kinase, and FGFR4-related cancers. Its proprietary SNAP platform uses iterative molecular snapshots to accelerate structural drug design.
Tyra Biosciences was incorporated in 2021 and operates out of Carlsbad, California.
- TYRA-300: selective FGFR3 inhibitor for bladder cancer
- FGFR2 program targeting intrahepatic cholangiocarcinoma
- FGFR3 program for achondroplasia
- RET kinase and FGFR4 oncology programs
- SNAP platform for rapid molecular drug design
Is TYRA a Good Stock to Buy?
UQS Score rates TYRA as Poor overall, reflecting the early-stage nature of the business across most evaluated dimensions.
The one area where TYRA stands out relative to its profile is Risk, which is rated Good — suggesting the company's balance sheet and cash position offer a degree of near-term stability uncommon for preclinical biotechs. This provides some runway for pipeline advancement.
Quality, Moat, and Growth are all rated Weak, consistent with a company that has no approved products, no revenue, and an unproven competitive position. Valuation is rated Elevated, meaning the current market price may already reflect optimistic pipeline assumptions.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TYRA pay dividends?
No — Tyra Biosciences, Inc. does not currently pay a dividend.
TYRA does not pay a dividend, which is standard for preclinical-stage biotechnology companies. All available capital is directed toward research, clinical development, and operational expenses. Investors in early-stage biotech typically seek returns through pipeline milestones and potential stock appreciation rather than income distributions.
When does TYRA report earnings?
Tyra Biosciences reports financial results on a quarterly cadence, typical for US-listed equities.
As a preclinical company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline progress rather than revenue or profitability. Key updates tend to center on clinical trial enrollment and data readouts rather than traditional financial performance.
For the most recent quarter's results and pipeline updates, visit Tyra Biosciences' investor relations page directly.
TYRA Price History
+108.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Tyra Biosciences, Inc.?
Based on Tyra Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TYRA Long-term Outlook
With Growth and Quality both rated Weak, the near-term fundamental outlook for TYRA is heavily dependent on clinical trial outcomes rather than organic business expansion. The Good Risk rating suggests the company has sufficient resources to continue operations, but the path to value creation runs through regulatory and clinical milestones. Elevated Valuation indicates the market may already be pricing in favorable pipeline scenarios, leaving limited margin for error if trials disappoint.
Growth drivers
- Positive clinical data readouts from the TYRA-300 bladder cancer program
- Expansion of the SNAP platform into additional oncology targets
- Potential partnership or licensing deals that validate the pipeline
Key risks
- Clinical trial failure or delays across any lead program
- Elevated valuation leaves little buffer if pipeline progress stalls
- Ongoing cash burn with no commercial revenue to offset expenses
TYRA vs Peers
TYRA operates in a competitive specialty biopharmaceutical space alongside other clinical and preclinical-stage companies targeting rare diseases and oncology.
Galapagos is a more established European biotech with a broader pipeline and existing commercial infrastructure, giving it a different risk-reward profile than early-stage TYRA.
AnaptysBio focuses on inflammation and immuno-oncology using antibody discovery technology, representing a distinct therapeutic approach compared to TYRA's FGFR inhibitor strategy.
Pharvaris targets hereditary angioedema with oral therapies, sharing the rare-disease focus but operating in a completely different disease area from TYRA's oncology programs.
Frequently Asked Questions
What does Tyra Biosciences do?
Tyra Biosciences is a preclinical-stage biopharmaceutical company developing targeted therapies to overcome tumor resistance in cancer. Its pipeline focuses on FGFR inhibitors for bladder cancer, cholangiocarcinoma, and achondroplasia, alongside RET kinase and FGFR4 programs. The company also uses its proprietary SNAP platform to accelerate drug design.
Does TYRA pay dividends?
No, TYRA does not pay a dividend. As a preclinical-stage biotech with no commercial revenue, the company directs all capital toward research and development. Dividend payments are not typical for companies at this stage of development.
When does TYRA report earnings?
Tyra Biosciences reports financial results on a quarterly cadence, standard for US-listed companies. Because it is preclinical, reports focus on cash position and pipeline updates rather than revenue. Check the company's investor relations page for the latest schedule and results.
Is TYRA a good stock to buy?
UQS Score rates TYRA as Poor overall. The Risk pillar is rated Good, suggesting near-term financial stability, but Quality, Moat, and Growth are all Weak, and Valuation is Elevated. Investors should weigh these factors carefully against their own risk tolerance before making a decision.
Is TYRA overvalued?
TYRA's Valuation pillar is rated Elevated within the UQS framework, suggesting the current market price may already reflect optimistic assumptions about pipeline success. For a preclinical company with no revenue, valuation is inherently speculative and tied to clinical outcomes.
How does TYRA compare to its competitors?
Compared to peers like Galapagos, AnaptysBio, and Pharvaris, TYRA is at an earlier stage of development with a narrower, more focused pipeline. Competitors may have more advanced clinical programs or commercial products, which generally translates to a different risk and quality profile.
What is TYRA's market cap bracket?
TYRA is classified as a small-cap stock. This places it in a category that typically carries higher volatility and liquidity risk compared to mid- or large-cap biotechs, though small-cap companies can also offer significant upside if clinical milestones are achieved.
Who founded Tyra Biosciences?
Tyra Biosciences was incorporated in 2021. For detailed information on the founding team and leadership history, the company's official website and SEC filings are the most reliable sources.
Is TYRA a long-term quality investment?
As a long-term quality indicator, TYRA's UQS Score of Poor reflects significant uncertainty across most pillars. The company's long-term prospects depend almost entirely on clinical trial outcomes. Investors focused on quality and durability may find the current profile challenging to justify without meaningful pipeline de-risking.
What is the main competitive advantage of Tyra Biosciences?
Tyra's primary differentiator is its SNAP platform, which uses iterative molecular snapshots to design highly selective FGFR inhibitors. This structural approach aims to improve selectivity and reduce off-target effects compared to earlier-generation FGFR therapies, though the platform remains unvalidated by commercial approval.
What sector does TYRA belong to?
TYRA operates in the Healthcare sector, specifically within the biopharmaceutical subsegment focused on oncology and rare diseases. It sits alongside other clinical and preclinical drug developers targeting FGFR-driven cancers and related conditions.
Is TYRA a growth stock or value stock?
Based on UQS pillar labels, TYRA does not fit neatly into either category. Growth is rated Weak given the absence of revenue, while Valuation is rated Elevated — meaning it carries a growth-stock price without the demonstrated growth to support it. This combination is common in early-stage biotech.
Unlock Full TYRA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare TYRA against peers on quality and risk
- ✓Track pipeline-stage biotech scores across the sector
- ✓Get the full analyst view available to Pro members
Pro Analysis
TYRA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 13.7 | 0.0 | 13.0 | 0.0 | 69.9 | 0.0 | 0.0 |
| Apr 2, 2026 | 13.7 | 0.0 | 13.0 | 0.0 | 69.6 | 0.0 | — |
TYRA — Pillar Breakdown
Quality
— 0.0/100 (25%)Tyra Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Tyra Biosciences, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.9/100 (15%)Tyra Biosciences, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Tyra Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Tyra Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TYRA.
Score Composition
Financial Data
More Stock Analysis
How is the TYRA UQS Score Calculated?
The UQS (Unified Quality Score) for Tyra Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Tyra Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Tyra Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.